- Cervical cancer is primarily caused by persistent infection with high-risk human papillomavirus (HPV) types. Drug treatment options include chemotherapy, immunotherapy, and targeted therapy, especially for late-stage or recurrent cervical cancer
- The market is being propelled by expanding access to cancer care, government vaccination initiatives, and rising investment in oncology R&D
- North America dominates the cervical cancer drug market with a market share of approximately 38.7%, supported by high awareness, robust screening programs, and access to advanced treatments.
- Asia-Pacific is projected to grow at the fastest pace and currently holds an estimated market share of 25.3%, driven by large patient pools and growing healthcare infrastructure.
- The immunotherapy segment is projected to grow at the highest CAGR of 13.7% during the forecast period due to increasing adoption of immune checkpoint inhibitors and novel monoclonal antibodies
